+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 7 Actively Recruiting clinical trials

A

Actively Recruiting

Transthyretin amyloidosis ATTR is a condition where the transthyretin protein breaks down and forms amyloid plaques that build up in organs, causing damage. There are two types wild-type ATTR, which occurs with aging, and variant ATTR caused by inherited defective TTR genes. This study focuses on adults who have inherited a pathogenic TTR gene variant but do not yet show symptoms, aiming to see if early treatment can prevent or delay disease development. The trial is a Phase 3, randomized, double-blind, placebo-controlled study evaluating prevention of ATTR cardiomyopathy and polyneuropathy. Participants will be randomly assigned to receive either acoramidis, a drug designed to stabilize the TTR protein and prevent amyloid formation, or a matching placebo. The study drug is taken orally twice daily at a dose equivalent to 800 mg acoramidis HCl BID. Participants will be adults aged 18 to 75 years whose age falls within 10 years younger or older than their predicted age of disease onset based on family history or actuarial tables. The trial will last approximately 7 years from randomization or until study end. During the study, participants will be monitored regularly with evaluations to detect the development of ATTR cardiomyopathy or polyneuropathy. Researchers will assess time to disease onset using centrally adjudicated criteria. Safety and adherence will be tracked throughout the trial. This long-term study will help determine if early treatment with acoramidis can delay or prevent symptoms in asymptomatic carriers of pathogenic TTR variants.

Age: 18Years - 75YearsAll GendersPhase 3
104 locations
S

Actively Recruiting

This research aims to compare the effects of oral anticoagulation versus no anticoagulation in patients aged 55 and older who have had recent episodes of transient atrial fibrillation triggered by stress and have additional factors that increase their risk of stroke. The study is a multinational, investigator-initiated, prospective, randomized, open-label trial evaluating the impact of non-vitamin K oral anticoagulants NOACs on preventing stroke and other serious cardiovascular events. Participants will be randomly assigned to either receive one of several NOACs, such as edoxaban, apixaban, dabigatran, or rivaroxaban, prescribed by their physician for the duration of the follow-up, or to a control group that will not receive anticoagulants unless medically indicated during the study. The choice of specific NOAC and dose adjustments are determined by the prescribing doctor. The study excludes patients with certain conditions like chronic atrial fibrillation, severe kidney or liver disease, recent cardiac surgery, or bleeding risks. During the study, participants will be monitored for up to 24 months to assess the occurrence of non-hemorrhagic stroke, systemic embolism, vascular mortality, myocardial infarction, peripheral arterial thrombosis, amputation, and venous thromboembolism. Regular follow-up will include evaluation of these outcomes to measure the effectiveness and safety of anticoagulation compared to no anticoagulation. Participants will provide informed consent and remain under medical supervision throughout the trial.

Age: 55Years +All GendersPhase 4
105 locations
E

Actively Recruiting

Researchers are evaluating a medicine called survodutide in adults aged 18 and older who have confirmed non-alcoholic steatohepatitis NASH or metabolic-associated steatohepatitis MASH with cirrhosis, and a body mass index BMI of 27 kgm2 or higher, or 25 kgm2 for Asian participants. The study aims to find out if survodutide helps improve liver function and related health outcomes in these individuals. People with other chronic liver diseases or high alcohol intake are not eligible to participate. Participants are randomly assigned to one of two groups one group receives once-weekly injections of survodutide, and the other group receives a placebo injection that looks the same but contains no medicine. Both groups receive counseling to encourage dietary changes and regular exercise. The study is double-blinded, meaning neither participants nor doctors know which treatment is given. The trial lasts up to 4 and a half years, with visits either in person or via video calls scheduled every 2, 4, or 6 weeks for about 17 months, then every 3 months afterwards. Throughout the study, researchers monitor participants health, body weight, and any side effects. They use imaging methods to measure liver parameters and collect symptom questionnaires. The main outcome measured is the time until serious liver-related events occur, such as liver transplant or worsening liver function. Secondary outcomes include changes in liver fibrosis, body weight, blood sugar control, liver stiffness, and other health markers. This thorough monitoring helps compare the effects of survodutide to placebo over the long term.

Age: 18Years +All GendersPhase 3
447 locations
E

Actively Recruiting

Researchers are studying adults aged 18 and older who live with obesity and have a liver disease known as non-alcoholic steatohepatitis NASH or metabolic associated steatohepatitis MASH with moderate or advanced liver fibrosis. The study aims to evaluate whether a medicine called survodutide can improve liver function in people with these conditions. It is a Phase III, randomized, double-blind, placebo-controlled trial conducted at multiple centers. Participants are randomly assigned to one of two groups one receives weekly injections of survodutide, and the other receives placebo injections that look the same but contain no medicine. The survodutide dose is gradually increased until reaching the target dose. All participants receive counseling on diet and exercise. The study includes two parts the first focuses on the effect of survodutide on NASH and fibrosis over one year, and the second assesses its long-term safety and effectiveness over up to seven years. Participants stay in the study for up to seven years, attending regular visits either in person or remotely via video call. Visits occur every two weeks initially, then every four to six weeks, and later every three months. Doctors monitor health, record any side effects, and measure body weight and digestive symptoms. Liver assessments include imaging and biopsies at selected visits. Participants also complete questionnaires about symptoms and quality of life. Researchers compare results between the groups to assess the medicines effects on liver health and related outcomes.

Age: 18Years +All GendersPhase 3
532 locations
E

Actively Recruiting

This research aims to evaluate the use of a lower INR target range 1.5 to 2.5 in patients who have a mechanical bileaflet heart valve implanted in the aortic position. The goal is to determine whether lowering the INR target can reduce bleeding risks without increasing the chance of blood clots or stroke. This study is important for patients who require lifelong warfarin treatment to prevent clot formation on their mechanical heart valves. Participants will be randomly assigned to one of two groups one group will have their warfarin dosing adjusted to maintain an INR target between 1.5 and 2.5, while the other group will follow the standard INR target range as currently recommended. Warfarin therapy is the main intervention, and the study compares these two INR target ranges to assess outcomes related to clotting and bleeding. Treatment and follow-up are expected to last about 2 to 3 years. Throughout the study, participants will be monitored for occurrences of thrombosis, thromboembolism, major and minor bleeding, strokes, heart attacks, and other complications. Researchers will track time spent in the therapeutic INR range and the incidence of extreme INR values. Safety and effectiveness assessments will continue through the study completion, which is anticipated to be approximately 2 to 3 years after enrollment.

Age: 18Years +All GendersPhase 3
45 locations
P

Actively Recruiting

Researchers are evaluating futibatinib, an oral FGFR inhibitor, in patients with advanced cholangiocarcinoma CCA that have FGFR2 gene fusions or rearrangements. This multinational Phase 2 study aims to confirm the clinical benefit of a 20 mg dose and assess the safety and effectiveness of a 16 mg dose in patients who have previously received treatment for their CCA. Participants are randomly assigned to one of two groups one receiving 16 mg of futibatinib daily and the other receiving 20 mg daily. Both treatments are taken orally every day in 21-day cycles. Patients may continue receiving the medication until their disease progresses or other withdrawal criteria are met. During the study, participants undergo assessments including imaging to measure tumor response, safety monitoring for side effects, and quality of life evaluations. Researchers will evaluate outcomes such as the objective response rate, duration of response, progression-free survival, overall survival, and adverse events up to 12 months after the study ends. The total participation duration depends on individual treatment response and disease progression.

Age: 18Years +All GendersPhase 2
65 locations
S

Actively Recruiting

This research aims to better understand congenital myotonic dystrophy CDM and childhood myotonic dystrophy ChDM, which are inherited disorders affecting multiple body systems in children. CDM appears at birth with serious symptoms like breathing problems and feeding difficulties, while ChDM begins after birth but before age 10 with similar but generally less severe effects. The study seeks to develop better clinical assessments and biomarkers for these conditions to aid future drug trials, especially since current adult trials cannot be directly applied to children due to differences in symptoms and disease progression. The study will enroll up to 200 children with either CDM or ChDM. No treatments are given as part of this study participants will continue to receive their usual medical care. Study visits will take place at the start of the study Baseline, and then again at 12 months and 24 months. During these visits, researchers will perform various physical and cognitive tests to track changes in mobility, muscle strength, language, sleepiness, behavior, and quality of life. Participants will be involved in detailed assessments including walking tests, motor function evaluations, hand strength measurements, and questionnaires on sleepiness and quality of life. Researchers will also monitor language abilities, repetitive behaviors, and adaptive skills. These evaluations will help measure changes over 24 months and improve the tools used in clinical trials for these diseases. The study is sponsored by Virginia Commonwealth University and is expected to continue through June 2030.

Age: 3Years - 17YearsAll Genders
4 locations